Femtosecond not always appropriate

Article

Although femtosecond lasers offer a strong alternative to microkeratomes, they are not suitable for every situation, according to Theo Seiler, MD.

Although femtosecond lasers offer a strong alternative to microkeratomes, they are not suitable for every situation, according to Theo Seiler, MD speaking at the German Ophthalmic Surgeons Meeting held in Nuremberg, Germany in May.

Dr Seiler offered this argument following a presentation by Thomas Neuhann, MD, who argued that femtosecond lasers are able to produce flaps of homogenous thickness and allow more precise flap placement, making them the favourable choice in his opinion.

Dr Seiler, however, discussed a number of studies that suggest that flap creation does not have a significant effect on visual outcomes. He also argued that the frequency of transient light sensitivity, although improved, is still a drawback.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.